From: Dietetic intervention in psoriatic arthritis: the DIETA trial
Placebo (n = 33) | Diet-fish (n = 32) | Diet-placebo (n = 32) | P | |
---|---|---|---|---|
Age (years) | 53.6 (10.2) | 54.6 (13.7) | 51.2 (15.1) | 0.591 |
Women, n (%) | 18 (54.5) | 17 (54.8) | 18 (54.5) | 1.001 |
Length joint disease (months) | 157.1 (133.9) | 162.8 (140.1) | 147.8 (231.4) | 0.181 |
Length skin disease (months) | 238.9 (162.8) | 216.8 (153.9) | 237.4 (227.1) | 0.871 |
Weight (kg) | 76.2 ± 16.2 | 76.5 ± 14.2 | 80.2 ± 16.1 | 0.571 |
Height (m) | 1.62 ± 0.09 | 1.60 ± 0.08 | 1.62 ± 0.01 | 0.761 |
Body Mass Index (kg/m2) | 28.9 ± 4.9 | 29.9 ± 5.3 | 30.5 ± 6.2 | 0.471 |
Waist Circumference (cm) | 101.8 ± 12.7 | 103.6 ± 12.8 | 104.1 ± 14.3 | 0.771 |
Comorbidities | ||||
Diabetes, n (%) | 8 (24.2) | 9 (28.1) | 3 (9.4) | 0.141 |
Hypertension, n (%) | 15 (45.5) | 15 (46.9) | 15 (46.9) | 1.001 |
Dyslipidemia, n (%) | 18 (54.5) | 12 (37.5) | 13 (39.4) | 0.271 |
Skin disease activity | ||||
PASI | 2.51 ± 3.79 | 3.41 ± 6.10 | 3.49 ± 6.31 | 0.921 |
BSA | 3.59 ± 7.04 | 3.74 ± 5.83 | 5.07 ± 12.6 | 0.801 |
Joint disease activity | ||||
DAS28-CRP | 2.93 ± 1.19 | 2.83 ± 1.55 | 2.98 ± 1.35 | 0.751 |
DAS28-ESR | 3.56 ± 1.32 | 3.31 ± 1.21 | 3.39 ± 1.60 | 0.611 |
Number of tender joints | 5.16 ± 6.95 | 2.53 ± 3.44 | 3.58 ± 4.32 | 0.121 |
Number of swollen joints | 2.91 ± 3.67 | 2.23 ± 2.60 | 2.30 ± 3.41 | 0.661 |
HAQ | 1.02 ± 0.73 | 0.84 ± 0.62 | 0.90 ± 0.71 | 0.521 |
PsA concomitant medications | ||||
GC, n (%) | 5 (15.2) | 3 (9.4) | 3 (9.4) | 0.661 |
NSAIDs, n (%) | 5 (15.2) | 5 (15.6) | 2 (6.3) | 0.421 |
Monotherapy (MTX, LEF or CsA), n (%) | 18 (54.5) | 23 (71.8) | 23 (71.8) | 0.231 |
TNF blockers, n (%) | 15 (45.4) | 12 (37.5) | 9 (28.1) | 0.801 |
TNF blockers plus MTX or LEF, n (%) | 7 (21.2) | 8 (25.0) | 6 (18.7) | 0.831 |
Physical activity (IPAQ) | ||||
Inactive | 21 (72.4) | 21 (72.4) | 18 (60.0) | 0.432 |
Minimally active | 7 (24.1) | 8 (27.6) | 12 (40.0) | 0.432 |
Sufficiently active | 1 (3.4) | 0 | 0 | 0.432 |
Active | 0 | 0 | 0 | 0.432 |
Very active | 0 | 0 | 0 | 0.432 |
MET-minutes/week | 945.1 ± 2544.7 | 781.3 ± 1366.9 | 817.9 ± 2167.3 | 0.951 |
Concomitant medications | ||||
Insulin, n (%) | 2 (6.1) | 4 (12.5) | 1 (3.1) | 0.331 |
Statins, n (%) | 10 (30.3) | 17 (53.1) | 6 (18.7) | 0.011 |
Antidiabetic, n (%) | 7 (21.2) | 10 (31.2) | 3 (9.4) | 0.091 |
Antihypertensive, n (%) | 14 (42.4) | 16 (50.0) | 16 (50.0) | 0.841 |
Biomarkers (12 h-fasting) | ||||
Triglycerides | 168.2 ± 105.8 | 112.11 ± 40.7 | 137.7 ± 91.1 | 0.031 |
Total Cholesterol | 196.6 ± 37.2 | 184.9 ± 44.5 | 205.9 ± 44.2 | 0.051 |
LDL-cholesterol | 115.5 ± 27.2 | 115,3 ± 41.4 | 130.6 ± 38.5 | 0.081 |
HDL-cholesterol | 45.1 ± 12 | 48.7 ± 11.1 | 49.5 ± 10.8 | 0.751 |
Glycemia | 102.8 ± 29.1 | 103.6 ± 31.0 | 102.3 ± 43.7 | 0.981 |
Insulin | 20.2 ± 17.1 | 17.1 ± 13.3 | 13.0 ± 10.2 | 0.131 |